THAR
Tharimmune, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.54
+6.63%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-9.0%
Return on equity
-6.9%
Return on assets
-5.1%
Return on invested capital
0.00x
Asset turnover
-$16.1M
Cash from operations
$2.73
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Dec 1, 2025